The global HPV vaccines market is projected to grow at a compound annual growth rate (CAGR) of approximately 8% from 2026 to 2034, reaching an estimated market size of $18.4 billion by 2034. This growth is driven by the increasing prevalence of HPV-associated cancers, such as cervical, anal, and oropharyngeal cancers, alongside expanding government immunization programs and support from global health organizations like WHO and Gavi. Advances in vaccine technology, including broader protection offered by nonavalent vaccines, and growing awareness of preventive healthcare are also key factors. North America currently leads the market, with significant contributions from Europe and Asia-Pacific, where vaccination efforts and healthcare infrastructure are improving rapidly.
Over the recent quarter, the BlackRock Health Sciences Term Trust increased its investments in pharmaceutical and biotechnology companies, initiating new positions in GSK and Vertex Pharmaceuticals due to strong fundamentals and progress in rare dise...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
The FTSE 100 rose modestly by 21 points to 10,459, supported by consumer defensive stocks like Bunzl and AstraZeneca, despite heavy losses in miners and tech funds. US and Asian tech stocks, including AI and semiconductor firms, sold off sharply, wit...
